Genta - Waiting For Genasense To Make Sense Trading Markets (press release), CA - At three years, 46% of the patients in the Genasense arm achieved overall survival, compared to only 37.5% of the patients in the chemotherapy arm ...OTC:GNTA
Learn how to survive a layoff Poughkeepsie Journal, NY - Here are some survival tips: In most states, there's a two- to three-week waiting period before benefits start, so the sooner you file, the sooner you'll ...
World marks AIDS Day TheChronicleHerald.ca, Canada - According to the Canadian AIDS Society, drug treatments have improved survival rates for those living with HIV, the virus linked to AIDS, and for people ...
Fight against cervical cancer Inquirer.net, Philippines - It is caused by a persistent and chronic infection caused by H.PV. or the human papilloma virus. The cancer is sexually transmitted by penetration or skin ...
Manage Your Energy vs Time Management Natural News.com, AZ - 29 minutes ago Over time, running on negative emotional energy at work or in any other area of life is a huge energy drain, which leads to chronic tiredness, perhaps even ...
Terminal Optimism, Terminal Hope Am J Psychiatry (subscription) - Although I had not treated her in many years, I had treated her for several years in the past. Although I completely understood the severity, gravity, ...
Genta - Waiting For Genasense To Make Sense RTT News, NY - On December 3, the FDA is expected to decide whether Genasense injection merits approval for Chronic Lymphocytic Leukemia. Genasense, known generically as ...OTC:GNTA
Doctors, researchers on quest for a cure News-Herald.com, OH - Nov 28, 2008 The five-year survival rate for breast cancer that has not spread beyond the breast has risen from 80 percent in the 1950s to 98 percent today, according to ...
Survival, plasma HIV-1 RNA concentrations and drug resistance in ... World Health Organization (press release), Switzerland - The authors report survival, plasma HIV-1 RNA concentrations and HIV-1 drug resistance patterns in 146 adolescents and youth aged 13?25 years who were ...
Providing Medicines For The Poor Chemical & Engineering News - Today, the medicines are so effective that HIV/AIDS is effectively now a chronic disease, with a significant quiver of first- and second-line drugs approved ...
Source: Google News
Recent News and Articles on the Keywords: gleevec + 0.21 + 3,000 Related to the article below (Last Update: 8/7/2008)
[CITATION] HMG Advance Access published February 6, 2006 O Maertens, H Prenen, M Debiec-Rychter, A Wozniak, … - Human Molecular Genetics - Oxford Univ Press -
Abstracts: Oral Presentations N Friday - Sarcoma, 2002 - informaworld.com ... 61% (p=0.4), respectively. There was no difference in 5 yr CDFS between the positive
vs. negative margin group, 61% vs. 68% (p=0.21), respectively. There was a ...
[PDF]ORAL PRESENTATIONS - N Friday, A Briccoli, M Rocca, S Galletti, P … - hindawi.com ... 61% (p=0.4), respectively. There was no difference in 5 yr CDFS between the positive
vs. negative margin group, 61% vs. 68% (p=0.21), respectively. There was a ... -
Synthesis and antiviral activities of new acyclic and ?double-headed? nucleoside analogues - X Zhang, A Amer, X Fan, J Balzarini, J Neyts, E De … - Bioorganic Chemistry, 2007 - Elsevier ... Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium ... 14] and tyrosine
kinase inhibitors (Gleevec, STI-571 ... as light yellow solid (0.21 g, 0.98 ... -
Source: Google Scholar
Chronic myelogenous leukaemia: after five years on Gleevec overall survival reaches 89 percent
A study of the Oregon Health & Science University ( OHSU ) Cancer Institute has shown that the overall survival of most people with chronic myelogenous leukemia ( CML ) treated with Imatinib ( Gleevec/Glivec, STI-571 ) is extremely high and the relapse rate is quite low.
The overall survival at five years is 89 percent as compared to no more than 50 percent with prior therapies, and the risk of relapse continues to decrease the longer patients take the drug.
" This represents a complete turn around in the prognosis for patients with this disease," said Brian J. Druker, at OHSU Cancer Institute and an investigator of the Howard Hughes Medical Institute.
Begun in June 2000, the IRIS ( International Randomized IFN vs. ST1571 ) trial involved 1,106 subjects at 117 centers in 16 countries. Subjects were in CML's chronic phase, the most common stage of the disease, and had not previously received chemotherapy.
Half were randomized to receive Imatinib and half to receive the standard treatment at the time the trial started, Interferon-alpha and Cytarabine arabinoside.
Participants in the Interferon arm were later allowed to cross over to Imatinib. Just 3 percent remain on Interferon therapy.
" Prior to this, we had to project what the five-year survival data would be and worried that the risk of relapse might increase. With this data, we have increased confidence in this targeted therapy," Druker said.
At five years, the overall survival of the 553 subjects randomized to receive Imatinib as their initial therapy was 89 percent; 95 percent if only deaths related to chronic myelogenous leukemia are considered.
Just 5 percent of subjects discontinued Imatinib because of side effects. Severe side effects included skin rashes, elevated liver enzymes and fluid retention. More common and less severe side effects included puffiness around the eyes, mild nausea, diarrhea and muscle cramps.
The risk of relapse has trended down during the past three years. In the study's fourth year, fewer than 1 percent of patients progressed from the chronic phase to the accelerated phase or to blast crisis. " This trend, if it holds, coupled with the low risk of relapse, means that the possibility of long-term survival with chronic myelogenous leukemia is increasingly likely," Druker said.
Clinical trials with Imatinib began a new era in cancer treatment in which cancerous cells are targeted based on their molecular abnormality and healthy cells are left unharmed.
In 2001, the FDA ( Food and Drug Administration ) broke a record for cancer therapy approval by fast-tracking Gleevec, approving it in less than three months for CML patients who failed Interferon.
Gleevec was approved for a rare and difficult to treat abdominal cancer, gastrointestinal stromal tumors ( GIST ), in 2002. In the following year, it also earned the FDA's approval for use in children, the first new pediatric cancer drug treatment in more than a decade.
